Many potential biomarkers for responsiveness or resistance to ICIs have been explored, such as tumor mutational burden (TMB) and tumor-infiltrating lymphocytes (TILs) [5], but only PDL1 expression is routinely used in first-line non-small cell lung cancer (NSCLC) and in cisplatin-ineligible urothelial carcinoma [6,7]. Here, CD274 is linked to urothelial carcinoma.